510 related articles for article (PubMed ID: 29364594)
1. Biosimilars in Dermatology - theory becomes reality.
Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
3. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in Dermatology: Current Situation (Part I).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):545-9. PubMed ID: 25987472
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars in Dermatology: Current Situation (Part II).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
[TBL] [Abstract][Full Text] [Related]
7. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars for the treatment of psoriasis.
Puig L; López-Ferrer A
Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
[No Abstract] [Full Text] [Related]
9. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
[TBL] [Abstract][Full Text] [Related]
10. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
11. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
Ruda RC; Kelly KA; Feldman SR
J Dermatolog Treat; 2023 Dec; 34(1):2140569. PubMed ID: 36305624
[TBL] [Abstract][Full Text] [Related]
13. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
Zhou X; Chen Z; Bi X
Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience.
Barker J; Girolomoni G; Egeberg A; Goncalves J; Pieper B; Kang T
J Dermatolog Treat; 2020 Dec; 31(8):794-800. PubMed ID: 31094242
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar medicines for psoriasis. Positioning of the Mexican Academy of Dermatology.
García-Hidalgo L; Méndez-Flores S; Carrillo-Vázquez S; Estrada-Aguilar L; García-Salazar MDR; Gómez-Flores M; López-Tello A; Charli-Joseph Y; Maldonado-García C; Serrano-Jaén L
Gac Med Mex; 2020; 156(Supl):1-14. PubMed ID: 32484168
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars for the treatment of psoriatic arthritis.
Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
[No Abstract] [Full Text] [Related]
18. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
19. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review.
Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ
Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071
[No Abstract] [Full Text] [Related]
20. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]